Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur l'Université de Trèves

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel

Identifieur interne : 000157 ( PascalFrancis/Corpus ); précédent : 000156; suivant : 000158

A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel

Auteurs : Pierre Maison-Blanche ; Jan B. Vermorken ; Tuncay Goksel ; Jean-Pascal Machiels ; Sanjiv Agarwala ; Sylvie Rottey ; Gedske Daugaard ; Constantin Volovat ; Max Scheulen ; Lisa Sengel V ; Dana Grecea ; Alexandru Eniu ; Elke J Ger ; Eyal Meiri ; Stefano Cascinu ; Dirk Strumberg ; Gokhan Demir ; Michael Clemens ; Graziella Pinotti ; Mario Nardi ; Troy Guthrie ; Emmanuelle Boelle ; Emmanuelle Magherini

Source :

RBID : Pascal:13-0254044

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0160-2446
A02 01      @0 JCPCDT
A03   1    @0 J. cardiovasc. pharmacol.
A05       @2 61
A06       @2 6
A08 01  1  ENG  @1 A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel
A11 01  1    @1 MAISON-BLANCHE (Pierre)
A11 02  1    @1 VERMORKEN (Jan B.)
A11 03  1    @1 GOKSEL (Tuncay)
A11 04  1    @1 MACHIELS (Jean-Pascal)
A11 05  1    @1 AGARWALA (Sanjiv)
A11 06  1    @1 ROTTEY (Sylvie)
A11 07  1    @1 DAUGAARD (Gedske)
A11 08  1    @1 VOLOVAT (Constantin)
A11 09  1    @1 SCHEULEN (Max)
A11 10  1    @1 SENGELØV (Lisa)
A11 11  1    @1 GRECEA (Dana)
A11 12  1    @1 ENIU (Alexandru)
A11 13  1    @1 JÄGER (Elke)
A11 14  1    @1 MEIRI (Eyal)
A11 15  1    @1 CASCINU (Stefano)
A11 16  1    @1 STRUMBERG (Dirk)
A11 17  1    @1 DEMIR (Gokhan)
A11 18  1    @1 CLEMENS (Michael)
A11 19  1    @1 PINOTTI (Graziella)
A11 20  1    @1 NARDI (Mario)
A11 21  1    @1 GUTHRIE (Troy)
A11 22  1    @1 BOELLE (Emmanuelle)
A11 23  1    @1 MAGHERINI (Emmanuelle)
A14 01      @1 Hôpital Bichat-Claude Bernard, Cardiology Department @2 Paris @3 FRA @Z 1 aut.
A14 02      @1 Antwerpen University Hospital, Department of Medical Oncology @2 Edegem @3 BEL @Z 2 aut.
A14 03      @1 Ege Universitesi Tip Fakultesi Gogus Hast A.D., Department of Pulmonary Medicine Izmir @3 TUR @Z 3 aut.
A14 04      @1 Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Department of Medical Oncology @2 Brussels @3 BEL @Z 4 aut.
A14 05      @1 St Luke's Hospital, Oncology and Hematology @2 Bethlehem, PA @3 USA @Z 5 aut.
A14 06      @1 Ghent University Hospital, Department of Medical Oncology @2 Ghent @3 BEL @Z 6 aut.
A14 07      @1 Rigshospitalet, Department of Oncology @2 Copenhagen @3 DNK @Z 7 aut.
A14 08      @1 Center of Medical Oncology Iasi @2 Iasi @3 ROU @Z 8 aut.
A14 09      @1 West German Cancer Center, Universitätsklinikum Essen, Innere Klinik (Tumorforschung) @2 Essen @3 DEU @Z 9 aut.
A14 10      @1 Herlev Hospital, Department of Oncology, Department of Breast Tumors @2 Herlev @3 DNK @Z 10 aut.
A14 11      @1 Institute of Oncology "prof Dr I Chiricuta" @2 Cluj Napoca @3 ROU @Z 11 aut. @Z 12 aut.
A14 12      @1 Krankenhaus Nordwest, Medizinische Klinik II, Department of Hematology-Oncology @2 Frankfurt Am Main @3 DEU @Z 13 aut.
A14 13      @1 Palm Beach Institute of Hematology and Oncology @2 Boynton Beach, Florida @3 USA @Z 14 aut.
A14 14      @1 Azienda Ospedaliero-Universitaria Ospedali Riuniti, Clinica di Oncologia Medica @2 Ancona @3 ITA @Z 15 aut.
A14 15      @1 Marienhospital Heme, Department of Hematology and Medical Oncology @2 Heme @3 DEU @Z 16 aut.
A14 16      @1 Istanbul Bilim Universitesi Tip Fakultesi, Department of Medical Oncology @2 Istanbul @3 TUR @Z 17 aut.
A14 17      @1 Klinikum Mutterhaus der Borromäerinnen, Klinik fur Innere Medizin I @2 Trier @3 DEU @Z 18 aut.
A14 18      @1 Ospedale Di Circolo E Fondazione Macchi @2 Varese @3 ITA @Z 19 aut.
A14 19      @1 Azienda Ospedaliera Bianchi Melacrino Morelli, Divisione di Oncologia @2 Reggio di Calabria @3 ITA @Z 20 aut.
A14 20      @1 Baptist Regional Cancer Institute @2 Jacksonville, FL @3 USA @Z 21 aut.
A14 21      @1 Sanofi R&D, R&D Oncology Division @2 Vitry-sur-Seine @3 FRA @Z 22 aut. @Z 23 aut.
A20       @1 495-504
A21       @1 2013
A23 01      @0 ENG
A43 01      @1 INIST @2 18065 @5 354000503621940070
A44       @0 0000 @1 © 2013 INIST-CNRS. All rights reserved.
A45       @0 20 ref.
A47 01  1    @0 13-0254044
A60       @1 P
A61       @0 A
A64 01  1    @0 Journal of cardiovascular pharmacology
A66 01      @0 USA
C02 01  X    @0 002B02F
C02 02  X    @0 002B12A02
C02 03  X    @0 002B04C
C03 01  X  FRE  @0 Randomisation @5 01
C03 01  X  ENG  @0 Randomization @5 01
C03 01  X  SPA  @0 Aleatorización @5 01
C03 02  X  FRE  @0 Etude double insu @5 02
C03 02  X  ENG  @0 Double blind study @5 02
C03 02  X  SPA  @0 Estudio doble ciego @5 02
C03 03  X  FRE  @0 Placebo @5 03
C03 03  X  ENG  @0 Placebo @5 03
C03 03  X  SPA  @0 Placebo @5 03
C03 04  X  FRE  @0 QT long @5 04
C03 04  X  ENG  @0 Prolonged QT interval @5 04
C03 04  X  SPA  @0 QT largo @5 04
C03 05  X  FRE  @0 Aflibercept @2 FR @5 05
C03 05  X  ENG  @0 Aflibercept @2 FR @5 05
C03 05  X  SPA  @0 Aflibercept @2 FR @5 05
C03 06  X  FRE  @0 Tumeur maligne @2 NM @5 06
C03 06  X  ENG  @0 Malignant tumor @2 NM @5 06
C03 06  X  SPA  @0 Tumor maligno @2 NM @5 06
C03 07  X  FRE  @0 Homme @5 08
C03 07  X  ENG  @0 Human @5 08
C03 07  X  SPA  @0 Hombre @5 08
C03 08  X  FRE  @0 Malade @5 09
C03 08  X  ENG  @0 Patient @5 09
C03 08  X  SPA  @0 Enfermo @5 09
C03 09  X  FRE  @0 Docétaxel @2 NK @2 FR @5 10
C03 09  X  ENG  @0 Docetaxel @2 NK @2 FR @5 10
C03 09  X  SPA  @0 Docetaxel @2 NK @2 FR @5 10
C03 10  X  FRE  @0 Coeur @5 11
C03 10  X  ENG  @0 Heart @5 11
C03 10  X  SPA  @0 Corazón @5 11
C03 11  X  FRE  @0 Toxicité @5 12
C03 11  X  ENG  @0 Toxicity @5 12
C03 11  X  SPA  @0 Toxicidad @5 12
C03 12  X  FRE  @0 Tumeur solide @5 13
C03 12  X  ENG  @0 Solid tumor @5 13
C03 12  X  SPA  @0 Tumor sólido @5 13
C03 13  X  FRE  @0 Intervalle QT @5 14
C03 13  X  ENG  @0 QT interval @5 14
C03 13  X  SPA  @0 Intervalo QT @5 14
C03 14  X  FRE  @0 Antiangiogénique @2 FR @5 23
C03 14  X  ENG  @0 Antiangiogenic agent @2 FR @5 23
C03 14  X  SPA  @0 Antiangiogenico @2 FR @5 23
C03 15  X  FRE  @0 Anticancéreux @5 24
C03 15  X  ENG  @0 Antineoplastic agent @5 24
C03 15  X  SPA  @0 Anticanceroso @5 24
C03 16  X  FRE  @0 Anti-VEGF @4 CD @5 96
C03 16  X  ENG  @0 Anti-VEGF @4 CD @5 96
C03 16  X  SPA  @0 Anti-VEGF @4 CD @5 96
C07 01  X  FRE  @0 Cancer @2 NM
C07 01  X  ENG  @0 Cancer @2 NM
C07 01  X  SPA  @0 Cáncer @2 NM
C07 02  X  FRE  @0 Pathologie de l'appareil circulatoire @5 37
C07 02  X  ENG  @0 Cardiovascular disease @5 37
C07 02  X  SPA  @0 Aparato circulatorio patología @5 37
C07 03  X  FRE  @0 Bloc cardiaque @5 38
C07 03  X  ENG  @0 Heart block @5 38
C07 03  X  SPA  @0 Bloque cardíaco @5 38
C07 04  X  FRE  @0 Cardiopathie @5 39
C07 04  X  ENG  @0 Heart disease @5 39
C07 04  X  SPA  @0 Cardiopatía @5 39
C07 05  X  FRE  @0 Trouble de la conduction @5 40
C07 05  X  ENG  @0 Conduction disorder @5 40
C07 05  X  SPA  @0 Trastorno conducción @5 40
C07 06  X  FRE  @0 Trouble du rythme cardiaque @5 41
C07 06  X  ENG  @0 Arrhythmia @5 41
C07 06  X  SPA  @0 Arritmia @5 41
C07 07  X  FRE  @0 Protéine fusion @5 42
C07 07  X  ENG  @0 Fusion protein @5 42
C07 07  X  SPA  @0 Proteína fusionada @5 42
C07 08  X  FRE  @0 Antimitotique @5 43
C07 08  X  ENG  @0 Antimitotic @5 43
C07 08  X  SPA  @0 Antimitótico @5 43
C07 09  X  FRE  @0 Dérivé du taxane @5 44
C07 09  X  ENG  @0 Taxane derivatives @5 44
C07 09  X  SPA  @0 Taxane derivado @5 44
C07 10  X  FRE  @0 Appareil circulatoire @5 45
C07 10  X  ENG  @0 Circulatory system @5 45
C07 10  X  SPA  @0 Aparato circulatorio @5 45
N21       @1 245
N44 01      @1 OTO
N82       @1 OTO

Format Inist (serveur)

NO : PASCAL 13-0254044 INIST
ET : A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel
AU : MAISON-BLANCHE (Pierre); VERMORKEN (Jan B.); GOKSEL (Tuncay); MACHIELS (Jean-Pascal); AGARWALA (Sanjiv); ROTTEY (Sylvie); DAUGAARD (Gedske); VOLOVAT (Constantin); SCHEULEN (Max); SENGELØV (Lisa); GRECEA (Dana); ENIU (Alexandru); JÄGER (Elke); MEIRI (Eyal); CASCINU (Stefano); STRUMBERG (Dirk); DEMIR (Gokhan); CLEMENS (Michael); PINOTTI (Graziella); NARDI (Mario); GUTHRIE (Troy); BOELLE (Emmanuelle); MAGHERINI (Emmanuelle)
AF : Hôpital Bichat-Claude Bernard, Cardiology Department/Paris/France (1 aut.); Antwerpen University Hospital, Department of Medical Oncology/Edegem/Belgique (2 aut.); Ege Universitesi Tip Fakultesi Gogus Hast A.D., Department of Pulmonary Medicine Izmir/Turquie (3 aut.); Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Department of Medical Oncology/Brussels/Belgique (4 aut.); St Luke's Hospital, Oncology and Hematology/Bethlehem, PA/Etats-Unis (5 aut.); Ghent University Hospital, Department of Medical Oncology/Ghent/Belgique (6 aut.); Rigshospitalet, Department of Oncology/Copenhagen/Danemark (7 aut.); Center of Medical Oncology Iasi/Iasi/Roumanie (8 aut.); West German Cancer Center, Universitätsklinikum Essen, Innere Klinik (Tumorforschung)/Essen/Allemagne (9 aut.); Herlev Hospital, Department of Oncology, Department of Breast Tumors/Herlev/Danemark (10 aut.); Institute of Oncology "prof Dr I Chiricuta"/Cluj Napoca/Roumanie (11 aut., 12 aut.); Krankenhaus Nordwest, Medizinische Klinik II, Department of Hematology-Oncology/Frankfurt Am Main/Allemagne (13 aut.); Palm Beach Institute of Hematology and Oncology/Boynton Beach, Florida/Etats-Unis (14 aut.); Azienda Ospedaliero-Universitaria Ospedali Riuniti, Clinica di Oncologia Medica/Ancona/Italie (15 aut.); Marienhospital Heme, Department of Hematology and Medical Oncology/Heme/Allemagne (16 aut.); Istanbul Bilim Universitesi Tip Fakultesi, Department of Medical Oncology/Istanbul/Turquie (17 aut.); Klinikum Mutterhaus der Borromäerinnen, Klinik fur Innere Medizin I/Trier/Allemagne (18 aut.); Ospedale Di Circolo E Fondazione Macchi/Varese/Italie (19 aut.); Azienda Ospedaliera Bianchi Melacrino Morelli, Divisione di Oncologia/Reggio di Calabria/Italie (20 aut.); Baptist Regional Cancer Institute/Jacksonville, FL/Etats-Unis (21 aut.); Sanofi R&D, R&D Oncology Division/Vitry-sur-Seine/France (22 aut., 23 aut.)
DT : Publication en série; Niveau analytique
SO : Journal of cardiovascular pharmacology; ISSN 0160-2446; Coden JCPCDT; Etats-Unis; Da. 2013; Vol. 61; No. 6; Pp. 495-504; Bibl. 20 ref.
LA : Anglais
CC : 002B02F; 002B12A02; 002B04C
FD : Randomisation; Etude double insu; Placebo; QT long; Aflibercept; Tumeur maligne; Homme; Malade; Docétaxel; Coeur; Toxicité; Tumeur solide; Intervalle QT; Antiangiogénique; Anticancéreux; Anti-VEGF
FG : Cancer; Pathologie de l'appareil circulatoire; Bloc cardiaque; Cardiopathie; Trouble de la conduction; Trouble du rythme cardiaque; Protéine fusion; Antimitotique; Dérivé du taxane; Appareil circulatoire
ED : Randomization; Double blind study; Placebo; Prolonged QT interval; Aflibercept; Malignant tumor; Human; Patient; Docetaxel; Heart; Toxicity; Solid tumor; QT interval; Antiangiogenic agent; Antineoplastic agent; Anti-VEGF
EG : Cancer; Cardiovascular disease; Heart block; Heart disease; Conduction disorder; Arrhythmia; Fusion protein; Antimitotic; Taxane derivatives; Circulatory system
SD : Aleatorización; Estudio doble ciego; Placebo; QT largo; Aflibercept; Tumor maligno; Hombre; Enfermo; Docetaxel; Corazón; Toxicidad; Tumor sólido; Intervalo QT; Antiangiogenico; Anticanceroso; Anti-VEGF
LO : INIST-18065.354000503621940070
ID : 13-0254044

Links to Exploration step

Pascal:13-0254044

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel</title>
<author>
<name sortKey="Maison Blanche, Pierre" sort="Maison Blanche, Pierre" uniqKey="Maison Blanche P" first="Pierre" last="Maison-Blanche">Pierre Maison-Blanche</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Hôpital Bichat-Claude Bernard, Cardiology Department</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Vermorken, Jan B" sort="Vermorken, Jan B" uniqKey="Vermorken J" first="Jan B." last="Vermorken">Jan B. Vermorken</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Antwerpen University Hospital, Department of Medical Oncology</s1>
<s2>Edegem</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Goksel, Tuncay" sort="Goksel, Tuncay" uniqKey="Goksel T" first="Tuncay" last="Goksel">Tuncay Goksel</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Ege Universitesi Tip Fakultesi Gogus Hast A.D., Department of Pulmonary Medicine Izmir</s1>
<s3>TUR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Machiels, Jean Pascal" sort="Machiels, Jean Pascal" uniqKey="Machiels J" first="Jean-Pascal" last="Machiels">Jean-Pascal Machiels</name>
<affiliation>
<inist:fA14 i1="04">
<s1>Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Department of Medical Oncology</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Agarwala, Sanjiv" sort="Agarwala, Sanjiv" uniqKey="Agarwala S" first="Sanjiv" last="Agarwala">Sanjiv Agarwala</name>
<affiliation>
<inist:fA14 i1="05">
<s1>St Luke's Hospital, Oncology and Hematology</s1>
<s2>Bethlehem, PA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Rottey, Sylvie" sort="Rottey, Sylvie" uniqKey="Rottey S" first="Sylvie" last="Rottey">Sylvie Rottey</name>
<affiliation>
<inist:fA14 i1="06">
<s1>Ghent University Hospital, Department of Medical Oncology</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Daugaard, Gedske" sort="Daugaard, Gedske" uniqKey="Daugaard G" first="Gedske" last="Daugaard">Gedske Daugaard</name>
<affiliation>
<inist:fA14 i1="07">
<s1>Rigshospitalet, Department of Oncology</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Volovat, Constantin" sort="Volovat, Constantin" uniqKey="Volovat C" first="Constantin" last="Volovat">Constantin Volovat</name>
<affiliation>
<inist:fA14 i1="08">
<s1>Center of Medical Oncology Iasi</s1>
<s2>Iasi</s2>
<s3>ROU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Scheulen, Max" sort="Scheulen, Max" uniqKey="Scheulen M" first="Max" last="Scheulen">Max Scheulen</name>
<affiliation>
<inist:fA14 i1="09">
<s1>West German Cancer Center, Universitätsklinikum Essen, Innere Klinik (Tumorforschung)</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Sengel V, Lisa" sort="Sengel V, Lisa" uniqKey="Sengel V L" first="Lisa" last="Sengel V">Lisa Sengel V</name>
<affiliation>
<inist:fA14 i1="10">
<s1>Herlev Hospital, Department of Oncology, Department of Breast Tumors</s1>
<s2>Herlev</s2>
<s3>DNK</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Grecea, Dana" sort="Grecea, Dana" uniqKey="Grecea D" first="Dana" last="Grecea">Dana Grecea</name>
<affiliation>
<inist:fA14 i1="11">
<s1>Institute of Oncology "prof Dr I Chiricuta"</s1>
<s2>Cluj Napoca</s2>
<s3>ROU</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Eniu, Alexandru" sort="Eniu, Alexandru" uniqKey="Eniu A" first="Alexandru" last="Eniu">Alexandru Eniu</name>
<affiliation>
<inist:fA14 i1="11">
<s1>Institute of Oncology "prof Dr I Chiricuta"</s1>
<s2>Cluj Napoca</s2>
<s3>ROU</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="J Ger, Elke" sort="J Ger, Elke" uniqKey="J Ger E" first="Elke" last="J Ger">Elke J Ger</name>
<affiliation>
<inist:fA14 i1="12">
<s1>Krankenhaus Nordwest, Medizinische Klinik II, Department of Hematology-Oncology</s1>
<s2>Frankfurt Am Main</s2>
<s3>DEU</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Meiri, Eyal" sort="Meiri, Eyal" uniqKey="Meiri E" first="Eyal" last="Meiri">Eyal Meiri</name>
<affiliation>
<inist:fA14 i1="13">
<s1>Palm Beach Institute of Hematology and Oncology</s1>
<s2>Boynton Beach, Florida</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Cascinu, Stefano" sort="Cascinu, Stefano" uniqKey="Cascinu S" first="Stefano" last="Cascinu">Stefano Cascinu</name>
<affiliation>
<inist:fA14 i1="14">
<s1>Azienda Ospedaliero-Universitaria Ospedali Riuniti, Clinica di Oncologia Medica</s1>
<s2>Ancona</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Strumberg, Dirk" sort="Strumberg, Dirk" uniqKey="Strumberg D" first="Dirk" last="Strumberg">Dirk Strumberg</name>
<affiliation>
<inist:fA14 i1="15">
<s1>Marienhospital Heme, Department of Hematology and Medical Oncology</s1>
<s2>Heme</s2>
<s3>DEU</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Demir, Gokhan" sort="Demir, Gokhan" uniqKey="Demir G" first="Gokhan" last="Demir">Gokhan Demir</name>
<affiliation>
<inist:fA14 i1="16">
<s1>Istanbul Bilim Universitesi Tip Fakultesi, Department of Medical Oncology</s1>
<s2>Istanbul</s2>
<s3>TUR</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Clemens, Michael" sort="Clemens, Michael" uniqKey="Clemens M" first="Michael" last="Clemens">Michael Clemens</name>
<affiliation>
<inist:fA14 i1="17">
<s1>Klinikum Mutterhaus der Borromäerinnen, Klinik fur Innere Medizin I</s1>
<s2>Trier</s2>
<s3>DEU</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Pinotti, Graziella" sort="Pinotti, Graziella" uniqKey="Pinotti G" first="Graziella" last="Pinotti">Graziella Pinotti</name>
<affiliation>
<inist:fA14 i1="18">
<s1>Ospedale Di Circolo E Fondazione Macchi</s1>
<s2>Varese</s2>
<s3>ITA</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Nardi, Mario" sort="Nardi, Mario" uniqKey="Nardi M" first="Mario" last="Nardi">Mario Nardi</name>
<affiliation>
<inist:fA14 i1="19">
<s1>Azienda Ospedaliera Bianchi Melacrino Morelli, Divisione di Oncologia</s1>
<s2>Reggio di Calabria</s2>
<s3>ITA</s3>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Guthrie, Troy" sort="Guthrie, Troy" uniqKey="Guthrie T" first="Troy" last="Guthrie">Troy Guthrie</name>
<affiliation>
<inist:fA14 i1="20">
<s1>Baptist Regional Cancer Institute</s1>
<s2>Jacksonville, FL</s2>
<s3>USA</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Boelle, Emmanuelle" sort="Boelle, Emmanuelle" uniqKey="Boelle E" first="Emmanuelle" last="Boelle">Emmanuelle Boelle</name>
<affiliation>
<inist:fA14 i1="21">
<s1>Sanofi R&D, R&D Oncology Division</s1>
<s2>Vitry-sur-Seine</s2>
<s3>FRA</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Magherini, Emmanuelle" sort="Magherini, Emmanuelle" uniqKey="Magherini E" first="Emmanuelle" last="Magherini">Emmanuelle Magherini</name>
<affiliation>
<inist:fA14 i1="21">
<s1>Sanofi R&D, R&D Oncology Division</s1>
<s2>Vitry-sur-Seine</s2>
<s3>FRA</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">13-0254044</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0254044 INIST</idno>
<idno type="RBID">Pascal:13-0254044</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000157</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel</title>
<author>
<name sortKey="Maison Blanche, Pierre" sort="Maison Blanche, Pierre" uniqKey="Maison Blanche P" first="Pierre" last="Maison-Blanche">Pierre Maison-Blanche</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Hôpital Bichat-Claude Bernard, Cardiology Department</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Vermorken, Jan B" sort="Vermorken, Jan B" uniqKey="Vermorken J" first="Jan B." last="Vermorken">Jan B. Vermorken</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Antwerpen University Hospital, Department of Medical Oncology</s1>
<s2>Edegem</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Goksel, Tuncay" sort="Goksel, Tuncay" uniqKey="Goksel T" first="Tuncay" last="Goksel">Tuncay Goksel</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Ege Universitesi Tip Fakultesi Gogus Hast A.D., Department of Pulmonary Medicine Izmir</s1>
<s3>TUR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Machiels, Jean Pascal" sort="Machiels, Jean Pascal" uniqKey="Machiels J" first="Jean-Pascal" last="Machiels">Jean-Pascal Machiels</name>
<affiliation>
<inist:fA14 i1="04">
<s1>Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Department of Medical Oncology</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Agarwala, Sanjiv" sort="Agarwala, Sanjiv" uniqKey="Agarwala S" first="Sanjiv" last="Agarwala">Sanjiv Agarwala</name>
<affiliation>
<inist:fA14 i1="05">
<s1>St Luke's Hospital, Oncology and Hematology</s1>
<s2>Bethlehem, PA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Rottey, Sylvie" sort="Rottey, Sylvie" uniqKey="Rottey S" first="Sylvie" last="Rottey">Sylvie Rottey</name>
<affiliation>
<inist:fA14 i1="06">
<s1>Ghent University Hospital, Department of Medical Oncology</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Daugaard, Gedske" sort="Daugaard, Gedske" uniqKey="Daugaard G" first="Gedske" last="Daugaard">Gedske Daugaard</name>
<affiliation>
<inist:fA14 i1="07">
<s1>Rigshospitalet, Department of Oncology</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Volovat, Constantin" sort="Volovat, Constantin" uniqKey="Volovat C" first="Constantin" last="Volovat">Constantin Volovat</name>
<affiliation>
<inist:fA14 i1="08">
<s1>Center of Medical Oncology Iasi</s1>
<s2>Iasi</s2>
<s3>ROU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Scheulen, Max" sort="Scheulen, Max" uniqKey="Scheulen M" first="Max" last="Scheulen">Max Scheulen</name>
<affiliation>
<inist:fA14 i1="09">
<s1>West German Cancer Center, Universitätsklinikum Essen, Innere Klinik (Tumorforschung)</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Sengel V, Lisa" sort="Sengel V, Lisa" uniqKey="Sengel V L" first="Lisa" last="Sengel V">Lisa Sengel V</name>
<affiliation>
<inist:fA14 i1="10">
<s1>Herlev Hospital, Department of Oncology, Department of Breast Tumors</s1>
<s2>Herlev</s2>
<s3>DNK</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Grecea, Dana" sort="Grecea, Dana" uniqKey="Grecea D" first="Dana" last="Grecea">Dana Grecea</name>
<affiliation>
<inist:fA14 i1="11">
<s1>Institute of Oncology "prof Dr I Chiricuta"</s1>
<s2>Cluj Napoca</s2>
<s3>ROU</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Eniu, Alexandru" sort="Eniu, Alexandru" uniqKey="Eniu A" first="Alexandru" last="Eniu">Alexandru Eniu</name>
<affiliation>
<inist:fA14 i1="11">
<s1>Institute of Oncology "prof Dr I Chiricuta"</s1>
<s2>Cluj Napoca</s2>
<s3>ROU</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="J Ger, Elke" sort="J Ger, Elke" uniqKey="J Ger E" first="Elke" last="J Ger">Elke J Ger</name>
<affiliation>
<inist:fA14 i1="12">
<s1>Krankenhaus Nordwest, Medizinische Klinik II, Department of Hematology-Oncology</s1>
<s2>Frankfurt Am Main</s2>
<s3>DEU</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Meiri, Eyal" sort="Meiri, Eyal" uniqKey="Meiri E" first="Eyal" last="Meiri">Eyal Meiri</name>
<affiliation>
<inist:fA14 i1="13">
<s1>Palm Beach Institute of Hematology and Oncology</s1>
<s2>Boynton Beach, Florida</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Cascinu, Stefano" sort="Cascinu, Stefano" uniqKey="Cascinu S" first="Stefano" last="Cascinu">Stefano Cascinu</name>
<affiliation>
<inist:fA14 i1="14">
<s1>Azienda Ospedaliero-Universitaria Ospedali Riuniti, Clinica di Oncologia Medica</s1>
<s2>Ancona</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Strumberg, Dirk" sort="Strumberg, Dirk" uniqKey="Strumberg D" first="Dirk" last="Strumberg">Dirk Strumberg</name>
<affiliation>
<inist:fA14 i1="15">
<s1>Marienhospital Heme, Department of Hematology and Medical Oncology</s1>
<s2>Heme</s2>
<s3>DEU</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Demir, Gokhan" sort="Demir, Gokhan" uniqKey="Demir G" first="Gokhan" last="Demir">Gokhan Demir</name>
<affiliation>
<inist:fA14 i1="16">
<s1>Istanbul Bilim Universitesi Tip Fakultesi, Department of Medical Oncology</s1>
<s2>Istanbul</s2>
<s3>TUR</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Clemens, Michael" sort="Clemens, Michael" uniqKey="Clemens M" first="Michael" last="Clemens">Michael Clemens</name>
<affiliation>
<inist:fA14 i1="17">
<s1>Klinikum Mutterhaus der Borromäerinnen, Klinik fur Innere Medizin I</s1>
<s2>Trier</s2>
<s3>DEU</s3>
<sZ>18 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Pinotti, Graziella" sort="Pinotti, Graziella" uniqKey="Pinotti G" first="Graziella" last="Pinotti">Graziella Pinotti</name>
<affiliation>
<inist:fA14 i1="18">
<s1>Ospedale Di Circolo E Fondazione Macchi</s1>
<s2>Varese</s2>
<s3>ITA</s3>
<sZ>19 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Nardi, Mario" sort="Nardi, Mario" uniqKey="Nardi M" first="Mario" last="Nardi">Mario Nardi</name>
<affiliation>
<inist:fA14 i1="19">
<s1>Azienda Ospedaliera Bianchi Melacrino Morelli, Divisione di Oncologia</s1>
<s2>Reggio di Calabria</s2>
<s3>ITA</s3>
<sZ>20 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Guthrie, Troy" sort="Guthrie, Troy" uniqKey="Guthrie T" first="Troy" last="Guthrie">Troy Guthrie</name>
<affiliation>
<inist:fA14 i1="20">
<s1>Baptist Regional Cancer Institute</s1>
<s2>Jacksonville, FL</s2>
<s3>USA</s3>
<sZ>21 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Boelle, Emmanuelle" sort="Boelle, Emmanuelle" uniqKey="Boelle E" first="Emmanuelle" last="Boelle">Emmanuelle Boelle</name>
<affiliation>
<inist:fA14 i1="21">
<s1>Sanofi R&D, R&D Oncology Division</s1>
<s2>Vitry-sur-Seine</s2>
<s3>FRA</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Magherini, Emmanuelle" sort="Magherini, Emmanuelle" uniqKey="Magherini E" first="Emmanuelle" last="Magherini">Emmanuelle Magherini</name>
<affiliation>
<inist:fA14 i1="21">
<s1>Sanofi R&D, R&D Oncology Division</s1>
<s2>Vitry-sur-Seine</s2>
<s3>FRA</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Journal of cardiovascular pharmacology</title>
<title level="j" type="abbreviated">J. cardiovasc. pharmacol.</title>
<idno type="ISSN">0160-2446</idno>
<imprint>
<date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Journal of cardiovascular pharmacology</title>
<title level="j" type="abbreviated">J. cardiovasc. pharmacol.</title>
<idno type="ISSN">0160-2446</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aflibercept</term>
<term>Anti-VEGF</term>
<term>Antiangiogenic agent</term>
<term>Antineoplastic agent</term>
<term>Docetaxel</term>
<term>Double blind study</term>
<term>Heart</term>
<term>Human</term>
<term>Malignant tumor</term>
<term>Patient</term>
<term>Placebo</term>
<term>Prolonged QT interval</term>
<term>QT interval</term>
<term>Randomization</term>
<term>Solid tumor</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Randomisation</term>
<term>Etude double insu</term>
<term>Placebo</term>
<term>QT long</term>
<term>Aflibercept</term>
<term>Tumeur maligne</term>
<term>Homme</term>
<term>Malade</term>
<term>Docétaxel</term>
<term>Coeur</term>
<term>Toxicité</term>
<term>Tumeur solide</term>
<term>Intervalle QT</term>
<term>Antiangiogénique</term>
<term>Anticancéreux</term>
<term>Anti-VEGF</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0160-2446</s0>
</fA01>
<fA02 i1="01">
<s0>JCPCDT</s0>
</fA02>
<fA03 i2="1">
<s0>J. cardiovasc. pharmacol.</s0>
</fA03>
<fA05>
<s2>61</s2>
</fA05>
<fA06>
<s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>MAISON-BLANCHE (Pierre)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>VERMORKEN (Jan B.)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>GOKSEL (Tuncay)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>MACHIELS (Jean-Pascal)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>AGARWALA (Sanjiv)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>ROTTEY (Sylvie)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>DAUGAARD (Gedske)</s1>
</fA11>
<fA11 i1="08" i2="1">
<s1>VOLOVAT (Constantin)</s1>
</fA11>
<fA11 i1="09" i2="1">
<s1>SCHEULEN (Max)</s1>
</fA11>
<fA11 i1="10" i2="1">
<s1>SENGELØV (Lisa)</s1>
</fA11>
<fA11 i1="11" i2="1">
<s1>GRECEA (Dana)</s1>
</fA11>
<fA11 i1="12" i2="1">
<s1>ENIU (Alexandru)</s1>
</fA11>
<fA11 i1="13" i2="1">
<s1>JÄGER (Elke)</s1>
</fA11>
<fA11 i1="14" i2="1">
<s1>MEIRI (Eyal)</s1>
</fA11>
<fA11 i1="15" i2="1">
<s1>CASCINU (Stefano)</s1>
</fA11>
<fA11 i1="16" i2="1">
<s1>STRUMBERG (Dirk)</s1>
</fA11>
<fA11 i1="17" i2="1">
<s1>DEMIR (Gokhan)</s1>
</fA11>
<fA11 i1="18" i2="1">
<s1>CLEMENS (Michael)</s1>
</fA11>
<fA11 i1="19" i2="1">
<s1>PINOTTI (Graziella)</s1>
</fA11>
<fA11 i1="20" i2="1">
<s1>NARDI (Mario)</s1>
</fA11>
<fA11 i1="21" i2="1">
<s1>GUTHRIE (Troy)</s1>
</fA11>
<fA11 i1="22" i2="1">
<s1>BOELLE (Emmanuelle)</s1>
</fA11>
<fA11 i1="23" i2="1">
<s1>MAGHERINI (Emmanuelle)</s1>
</fA11>
<fA14 i1="01">
<s1>Hôpital Bichat-Claude Bernard, Cardiology Department</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Antwerpen University Hospital, Department of Medical Oncology</s1>
<s2>Edegem</s2>
<s3>BEL</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Ege Universitesi Tip Fakultesi Gogus Hast A.D., Department of Pulmonary Medicine Izmir</s1>
<s3>TUR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Department of Medical Oncology</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05">
<s1>St Luke's Hospital, Oncology and Hematology</s1>
<s2>Bethlehem, PA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06">
<s1>Ghent University Hospital, Department of Medical Oncology</s1>
<s2>Ghent</s2>
<s3>BEL</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07">
<s1>Rigshospitalet, Department of Oncology</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08">
<s1>Center of Medical Oncology Iasi</s1>
<s2>Iasi</s2>
<s3>ROU</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09">
<s1>West German Cancer Center, Universitätsklinikum Essen, Innere Klinik (Tumorforschung)</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10">
<s1>Herlev Hospital, Department of Oncology, Department of Breast Tumors</s1>
<s2>Herlev</s2>
<s3>DNK</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="11">
<s1>Institute of Oncology "prof Dr I Chiricuta"</s1>
<s2>Cluj Napoca</s2>
<s3>ROU</s3>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="12">
<s1>Krankenhaus Nordwest, Medizinische Klinik II, Department of Hematology-Oncology</s1>
<s2>Frankfurt Am Main</s2>
<s3>DEU</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="13">
<s1>Palm Beach Institute of Hematology and Oncology</s1>
<s2>Boynton Beach, Florida</s2>
<s3>USA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="14">
<s1>Azienda Ospedaliero-Universitaria Ospedali Riuniti, Clinica di Oncologia Medica</s1>
<s2>Ancona</s2>
<s3>ITA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="15">
<s1>Marienhospital Heme, Department of Hematology and Medical Oncology</s1>
<s2>Heme</s2>
<s3>DEU</s3>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="16">
<s1>Istanbul Bilim Universitesi Tip Fakultesi, Department of Medical Oncology</s1>
<s2>Istanbul</s2>
<s3>TUR</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA14 i1="17">
<s1>Klinikum Mutterhaus der Borromäerinnen, Klinik fur Innere Medizin I</s1>
<s2>Trier</s2>
<s3>DEU</s3>
<sZ>18 aut.</sZ>
</fA14>
<fA14 i1="18">
<s1>Ospedale Di Circolo E Fondazione Macchi</s1>
<s2>Varese</s2>
<s3>ITA</s3>
<sZ>19 aut.</sZ>
</fA14>
<fA14 i1="19">
<s1>Azienda Ospedaliera Bianchi Melacrino Morelli, Divisione di Oncologia</s1>
<s2>Reggio di Calabria</s2>
<s3>ITA</s3>
<sZ>20 aut.</sZ>
</fA14>
<fA14 i1="20">
<s1>Baptist Regional Cancer Institute</s1>
<s2>Jacksonville, FL</s2>
<s3>USA</s3>
<sZ>21 aut.</sZ>
</fA14>
<fA14 i1="21">
<s1>Sanofi R&D, R&D Oncology Division</s1>
<s2>Vitry-sur-Seine</s2>
<s3>FRA</s3>
<sZ>22 aut.</sZ>
<sZ>23 aut.</sZ>
</fA14>
<fA20>
<s1>495-504</s1>
</fA20>
<fA21>
<s1>2013</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>18065</s2>
<s5>354000503621940070</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>13-0254044</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Journal of cardiovascular pharmacology</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X">
<s0>002B02F</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B12A02</s0>
</fC02>
<fC02 i1="03" i2="X">
<s0>002B04C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Randomisation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Randomization</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Aleatorización</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Etude double insu</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Double blind study</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Estudio doble ciego</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Placebo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Placebo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Placebo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>QT long</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Prolonged QT interval</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>QT largo</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Aflibercept</s0>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Aflibercept</s0>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Aflibercept</s0>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Homme</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Human</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Hombre</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Malade</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Patient</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Enfermo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Docétaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Docetaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Docetaxel</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Coeur</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Heart</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Corazón</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Toxicité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Toxicity</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Toxicidad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Tumeur solide</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Solid tumor</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Tumor sólido</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>Intervalle QT</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>QT interval</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>Intervalo QT</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE">
<s0>Antiangiogénique</s0>
<s2>FR</s2>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG">
<s0>Antiangiogenic agent</s0>
<s2>FR</s2>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA">
<s0>Antiangiogenico</s0>
<s2>FR</s2>
<s5>23</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE">
<s0>Anticancéreux</s0>
<s5>24</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG">
<s0>Antineoplastic agent</s0>
<s5>24</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA">
<s0>Anticanceroso</s0>
<s5>24</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE">
<s0>Anti-VEGF</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG">
<s0>Anti-VEGF</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA">
<s0>Anti-VEGF</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Pathologie de l'appareil circulatoire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Bloc cardiaque</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Heart block</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Bloque cardíaco</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Cardiopathie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Heart disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Cardiopatía</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Trouble de la conduction</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Conduction disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Trastorno conducción</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Trouble du rythme cardiaque</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Arrhythmia</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Arritmia</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Protéine fusion</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Fusion protein</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Proteína fusionada</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Antimitotique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Antimitotic</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Antimitótico</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Dérivé du taxane</s0>
<s5>44</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Taxane derivatives</s0>
<s5>44</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Taxane derivado</s0>
<s5>44</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Appareil circulatoire</s0>
<s5>45</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Circulatory system</s0>
<s5>45</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Aparato circulatorio</s0>
<s5>45</s5>
</fC07>
<fN21>
<s1>245</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 13-0254044 INIST</NO>
<ET>A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel</ET>
<AU>MAISON-BLANCHE (Pierre); VERMORKEN (Jan B.); GOKSEL (Tuncay); MACHIELS (Jean-Pascal); AGARWALA (Sanjiv); ROTTEY (Sylvie); DAUGAARD (Gedske); VOLOVAT (Constantin); SCHEULEN (Max); SENGELØV (Lisa); GRECEA (Dana); ENIU (Alexandru); JÄGER (Elke); MEIRI (Eyal); CASCINU (Stefano); STRUMBERG (Dirk); DEMIR (Gokhan); CLEMENS (Michael); PINOTTI (Graziella); NARDI (Mario); GUTHRIE (Troy); BOELLE (Emmanuelle); MAGHERINI (Emmanuelle)</AU>
<AF>Hôpital Bichat-Claude Bernard, Cardiology Department/Paris/France (1 aut.); Antwerpen University Hospital, Department of Medical Oncology/Edegem/Belgique (2 aut.); Ege Universitesi Tip Fakultesi Gogus Hast A.D., Department of Pulmonary Medicine Izmir/Turquie (3 aut.); Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Department of Medical Oncology/Brussels/Belgique (4 aut.); St Luke's Hospital, Oncology and Hematology/Bethlehem, PA/Etats-Unis (5 aut.); Ghent University Hospital, Department of Medical Oncology/Ghent/Belgique (6 aut.); Rigshospitalet, Department of Oncology/Copenhagen/Danemark (7 aut.); Center of Medical Oncology Iasi/Iasi/Roumanie (8 aut.); West German Cancer Center, Universitätsklinikum Essen, Innere Klinik (Tumorforschung)/Essen/Allemagne (9 aut.); Herlev Hospital, Department of Oncology, Department of Breast Tumors/Herlev/Danemark (10 aut.); Institute of Oncology "prof Dr I Chiricuta"/Cluj Napoca/Roumanie (11 aut., 12 aut.); Krankenhaus Nordwest, Medizinische Klinik II, Department of Hematology-Oncology/Frankfurt Am Main/Allemagne (13 aut.); Palm Beach Institute of Hematology and Oncology/Boynton Beach, Florida/Etats-Unis (14 aut.); Azienda Ospedaliero-Universitaria Ospedali Riuniti, Clinica di Oncologia Medica/Ancona/Italie (15 aut.); Marienhospital Heme, Department of Hematology and Medical Oncology/Heme/Allemagne (16 aut.); Istanbul Bilim Universitesi Tip Fakultesi, Department of Medical Oncology/Istanbul/Turquie (17 aut.); Klinikum Mutterhaus der Borromäerinnen, Klinik fur Innere Medizin I/Trier/Allemagne (18 aut.); Ospedale Di Circolo E Fondazione Macchi/Varese/Italie (19 aut.); Azienda Ospedaliera Bianchi Melacrino Morelli, Divisione di Oncologia/Reggio di Calabria/Italie (20 aut.); Baptist Regional Cancer Institute/Jacksonville, FL/Etats-Unis (21 aut.); Sanofi R&D, R&D Oncology Division/Vitry-sur-Seine/France (22 aut., 23 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of cardiovascular pharmacology; ISSN 0160-2446; Coden JCPCDT; Etats-Unis; Da. 2013; Vol. 61; No. 6; Pp. 495-504; Bibl. 20 ref.</SO>
<LA>Anglais</LA>
<CC>002B02F; 002B12A02; 002B04C</CC>
<FD>Randomisation; Etude double insu; Placebo; QT long; Aflibercept; Tumeur maligne; Homme; Malade; Docétaxel; Coeur; Toxicité; Tumeur solide; Intervalle QT; Antiangiogénique; Anticancéreux; Anti-VEGF</FD>
<FG>Cancer; Pathologie de l'appareil circulatoire; Bloc cardiaque; Cardiopathie; Trouble de la conduction; Trouble du rythme cardiaque; Protéine fusion; Antimitotique; Dérivé du taxane; Appareil circulatoire</FG>
<ED>Randomization; Double blind study; Placebo; Prolonged QT interval; Aflibercept; Malignant tumor; Human; Patient; Docetaxel; Heart; Toxicity; Solid tumor; QT interval; Antiangiogenic agent; Antineoplastic agent; Anti-VEGF</ED>
<EG>Cancer; Cardiovascular disease; Heart block; Heart disease; Conduction disorder; Arrhythmia; Fusion protein; Antimitotic; Taxane derivatives; Circulatory system</EG>
<SD>Aleatorización; Estudio doble ciego; Placebo; QT largo; Aflibercept; Tumor maligno; Hombre; Enfermo; Docetaxel; Corazón; Toxicidad; Tumor sólido; Intervalo QT; Antiangiogenico; Anticanceroso; Anti-VEGF</SD>
<LO>INIST-18065.354000503621940070</LO>
<ID>13-0254044</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000157 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000157 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Rhénanie
   |area=    UnivTrevesV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:13-0254044
   |texte=   A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel
}}
Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Jul 22 16:29:01 2017. Site generation: Wed Feb 28 14:55:37 2024